Why This Matters for Your Career
Aurobindo Pharma is hiring 4 roles related to this product
External Resources
LINACLOTIDE by Aurobindo Pharma is cyclase-c (gc-c) agonist. First approved in 2023.
Drug data last refreshed 22h ago
cyclase-C (GC-C) agonist. Both linaclotide and its active metabolitebind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Virtual Reality and Linaclotide for IBS-C
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
Evaluate the Safety of Linaclotide in IBS-C Patients in China
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
Worked on LINACLOTIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Aurobindo Pharma is hiring 4 roles related to this product